Reimagine Medicine | Novartis United States of America

Media Release
Apr 24, 2015
Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list
Media Release
Mar 31, 2015
Novartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
Media Release
Jun 12, 2015
Novartis presents new data at WCD that shows significant efficacy of Cosentyx® in patients with psoriasis of the palms, soles of feet and nails
Media Release
Jun 01, 2015
Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma
Media Release
May 31, 2015
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
Media Release
Sep 24, 2015
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
Media Release
Jul 24, 2015
FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Media Release
Jul 07, 2015
Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)
Media Release
Oct 27, 2015
Novartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
Media Release
Sep 30, 2015
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
Media Release
Sep 28, 2015
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Media Release
Nov 08, 2015
Up to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data

‹ Previous page
1
…
35
36
37
38
39
40
41
…
50
› Next page